Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DoTH: TIPS plus half-dose donafenib in advanced HCC
NCT06646198Phase 2Recruiting
- Start
- Oct 2024
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of donafenib in hepatocellular carcinoma (HCC). Primary endpoint: Objective Response Rate at 1 year. Started Oct 2024; status: recruiting.
02
Drugs
donafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06646198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06646198.